Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02397408 · ClinicalTrials.gov registry record · Phase 2
11C- and 18F-Choline PET/MR Imaging for Prostate Cancer
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT02397408: Completed Phase 2 study, sponsored by University of California, San Francisco.
NCT02397408 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 18 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02397408, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This phase II trial studies how well 11C-choline (carbon C 11 choline) and 18F-choline (fluorine F 18 choline) positron emission tomography/magnetic resonance (PET/MR) imaging works in diagnosing patients with unfavorable intermediate to high-risk prostate cancer. Diagnostic procedures, such as 11C- and 18F-choline PET/MR may help find and diagnose prostate cancer and find out how far the disease has spread.
Primary Outcome
The average K1 values of primary tumors will be reported along with the standard deviation
Interventions
- DRUG Carbon C 11 Choline
- DRUG Fluorine F 18 Choline
- PROCEDURE Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-04-09 |
| Est. Completion | 2015-06-30 |
| Phase | Phase 2 |
What the finished NCT02397408 record still lists
NCT02397408 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 3 interventions - of which Carbon C 11 Choline is the first listed.
NCT02397408 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02397408 about?
NCT02397408 is a clinical study titled "11C- and 18F-Choline PET/MR Imaging for Prostate Cancer". This phase II trial studies how well 11C-choline (carbon C 11 choline) and 18F-choline (fluorine F 18 choline) positron emission tomography/magnetic resonance (PET/MR) imaging works in diagnosing patients with unfavorable intermediate to high-risk prostate cancer. Diagnostic procedures, such as 11C-...
What is the current status of trial NCT02397408?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2015-04-09. Estimated completion is 2015-06-30.
What interventions are being tested in trial NCT02397408?
The interventions under investigation include: Carbon C 11 Choline (DRUG), Fluorine F 18 Choline (DRUG), Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI) (PROCEDURE).
Who is sponsoring clinical trial NCT02397408?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02397408's enrollment target sits among peer trials
18 1898th of 2000 higher than 98 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI